Stockscreener 앱 받기
1.02
8.11%
-0.09
시간 외 거래:
1.03
0.01
+0.98%
전일 마감가:
$1.11
열려 있는:
$1.13
하루 거래량:
362.02K
Relative Volume:
2.06
시가총액:
$42.71M
수익:
-
순이익/손실:
$-28.42M
주가수익비율:
-0.6703
EPS:
-1.5218
순현금흐름:
$-5.33M
1주 성능:
-14.29%
1개월 성능:
-15.35%
6개월 성능:
-18.40%
1년 성능:
-15.00%
1일 변동 폭
$1.00
$1.13
1주일 범위
$1.00
$1.24
52주 변동 폭
$0.73
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
명칭
Mira Pharmaceuticals Inc
전화
813-369-5150
주소
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.02 | 46.48M | 0 | -28.42M | -5.33M | -1.5218 |
|
LLY
Lilly Eli Co
|
917.50 | 819.81B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.60 | 571.52B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
206.23 | 368.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.93 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
148.19 | 285.86B | 54.72B | 14.02B | 15.32B | 7.1855 |
Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스
Dividend Watch: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Drops By 13.9% - MarketBeat
MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Ideas: What is the Moat Score of MIRA Pharmaceuticals IncTrade Exit Summary & Entry Point Confirmation Signals - baoquankhu1.vn
MIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trial - MSN
Wall Street Recap: What are MIRA Pharmaceuticals Incs recent SEC filings showing2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Winners Losers: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
MIRA completes Phase 1 trial of oral NMDA drug Ketamir-2 - Investing.com
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 - ACCESS Newswire
MIRA tests oral Ketamir-2 for chemo nerve pain after safe Phase 1 - Stock Titan
MIRA Pharmaceuticals, Inc. (MIRA) Competitors - Meyka
MIRA Completes Phase 1 Trial of Ketamir-2 Therapy - TipRanks
Mira Pharmaceuticals Inc completes phase 1 dosing of Ketamir-2SEC filing - marketscreener.com
Mira Pharmaceuticals IncCompletes Phase 1 Dosing Of Ketamir-2SEC Filing - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) finishes Ketamir-2 Phase 1 dosing with encouraging safety - Stock Titan
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February - MarketBeat
Ideas Watch: How does MIRA Pharmaceuticals Inc compare to its peersPortfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Risk Analysis: What is the Moat Score of MIRA Pharmaceuticals IncWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
MIRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug Summary: What are MIRA Pharmaceuticals Incs recent SEC filings showingJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M - MSN
What is MIRA Pharmaceuticals Inc. s revenue forecastEarnings Overview Report & Daily Price Action Insights - mfd.ru
MIRA PE Ratio & Valuation, Is MIRA Overvalued - Intellectia AI
What are MIRA Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Value Summary & High Conviction Buy Zone Alerts - mfd.ru
How does MIRA Pharmaceuticals Inc. compare to its peersJuly 2025 PreEarnings & Daily Technical Stock Forecast Reports - mfd.ru
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 6.6%Time to Sell? - MarketBeat
MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 6.6%Time to Sell? - MarketBeat
Bear Alert: How is GIGGW managing supply chain issues2025 Big Picture & Long Hold Capital Preservation Plans - baoquankhu1.vn
MIRA Pharmaceuticals initiates final dosing in phase 1 trial of Ketamir-2 - Investing.com Nigeria
MIRA Pharmaceuticals initiates final dosing in phase 1 trial of Ketamir-2 By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study - Rutland Herald
Cancer nerve pain has no approved drugs. Oral trial nears first-phase finish - Stock Titan
User - The Chronicle-Journal
MIRA Pharmaceuticals Advances Ketamir-2 Phase 1 to Final Cohort - TipRanks
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog - Pensacola News Journal
Value Recap: What is the Moat Score of MIRA Pharmaceuticals IncWeekly Trade Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Can MIRA Pharmaceuticals Inc. stock deliver consistent earnings growthGlobal Markets & Safe Entry Zone Identification - bollywoodhelpline.com
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Sees Significant Growth in Short Interest - Defense World
Nasdaq Moves: Is DiaMedica Therapeutics Inc a cyclical or defensive stockMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Big Picture: How does MIRA Pharmaceuticals Inc compare to its peersGap Down & Detailed Earnings Play Strategies - baoquankhu1.vn
Will MIRA Pharmaceuticals Inc. stock maintain dividend yieldWide Width Options & HOKA model picks for your routine - Улправда
Trendlines Suggest Garment Mantra Lifestyle Limited May Bottom Out Soon - Bollywood Helpline
2026 world cup usa national team qualification midfield leaders build up play winner prediction guideJuly 2025 Volume & Low Volatility Stock Recommendations - Улправда
2026 world cup mexico qualification playmakers low block knockout prediction analysis - Улправда
2026 world cup canada qualification match preview insightsIndex Update & Fast Entry and Exit Trade Plans - Улправда
Quarterly Risk: Will MIRA Pharmaceuticals Inc stock gain from strong economyJobs Report & Real-Time Buy Signal Alerts - Bộ Nội Vụ
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Update - MarketBeat
Resistance Break Could Fuel Unichem Laboratories Limited RallyEarnings Beat Highlights & Maximize Gains Professionally - Bollywood Helpline
Mira Pharmaceuticals approves CEO incentive awards including SKNY acquisition bonus By Investing.com - Investing.com South Africa
Mira Pharmaceuticals approves CEO incentive awards including SKNY acquisition bonus - Investing.com
Mira Pharmaceuticals Inc (MIRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
0.99%
자본화:
|
볼륨(24시간):